Expert Point of View: Axitinib Improves Progression-free Survival over Sorafenib in Advanced Renal Cell Carcinoma
According to Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, “These data show that treatment with a potent and specific antiangiogenic agent after immunotherapy does provide significant prolongation of progression-free survival, and that axitinib is clearly superior to sorafenib from a statistical and clinical perspective.” In the post–VEGF-targeted therapy scenario, he noted, the benefit of axitinib over sorafenib, while statistically significant, becomes somewhat less clinically relevant. “In tyrosine kinase inhibitor–refractory patients, everolimus provided a 4.9-month progression-free survival. Therefore, axitinib provides an alternative to everolimus in tyrosine kinase inhibitor–pretreated individuals, but it is not necessarily a paradigm shifting agent in that setting,” he added. “These data underscore the need for a better understanding of the resistance mechanisms after anti-VEGF therapy, which will guide our future therapy development,” said Dr. Jonasch. ■
Disclosure: Dr. Jonasch has served as a consultant for Pfizer, AVEO Pharmaceuticals, and GlaxoSmithKline, and has received research support from Pfizer, GlaxoSmithKline, and Novartis.
A randomized comparative effectiveness phase III trial demonstrated significantly superior efficacy for the tyrosine kinase inhibitor axitinib compared to sorafenib (Nexavar) in patients with advanced renal cell carcinoma (RCC). These data suggest that axitinib may become a new standard of care for ...